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and causes signiﬁcantly greater risks than beneﬁts. Even ignor-
ing alternative treatments for osteoporosis, not using HRT is a
dominant strategy in all age groups.
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OBJECTIVES: The objective was to estimate direct medical costs
for non-vertebral fractures in the ﬁrst year of therapy among rise-
dronate, alendronate, and nasal calcitonin patients utilizing an
integrated administrative, medical and pharmacy claims data-
base. METHODS: A retrospective cohort study was conducted
among 5024 women and men (aged 45+) with a new prescrip-
tion for risedronate (5mg/day, or 30mg/week), alendronate (5
mg/day, 10mg/day, 35mg/week or 70mg/week), or nasal calci-
tonin (200I.U./day) between July 1, 2000, and June 30, 2001.
Non-vertebral fracture-related direct medical costs (inpatient
and outpatient care) were assessed for a 12-month period fol-
lowing initiation of the bisphosphonate or nasal calcitonin
therapy using 2003 Medicare fee schedule payments. Sites at
which a patient had a clinical fracture in the 6 months prior to
initiation of therapy were excluded from the analysis. RESULTS:
During the capture period patients were treated with alendronate
(74%), risedronate (13%), and nasal calcitonin (13%). There
were no baseline differences in age, gender or number of con-
comitant medications between risedronate and alendronate
patients. Nasal calcitonin patients, however, were signiﬁcantly
older and had higher concomitant medications use than both
risedronate and alendronate patients. Alendronate patients
incurred almost three times the fracture-related costs of rise-
dronate patients ($124 vs. $45, p = 0.019). Nasal calcitonin
patients incurred more than four times the fracture-related costs
of risedronate patients ($198 vs. $45, p = 0.028) in an adjusted
model. Alendronate patients did not have signiﬁcantly different
fracture-related costs than nasal calcitonin patients. CONCLU-
SIONS: Observed fracture-related costs among patients initiat-
ing risedronate therapy were lower than fracture-related costs
among patients of similar characteristics who initiated alen-
dronate therapy.
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OBJECTIVES: Teriparatide has shown improved efﬁcacy in
increasing bone mineral density and decreasing nonvertebral
fractures in comparison to alendronate. The cost-effectiveness of
teriparatide over bisphosphonates has not been evaluated in the
VA Health System. This decision model seeks to evaluate all rel-
evant resource utilization and associated costs of osteoporosis
treatment with teriparatide compared to bisphosphonates to
determine the cost-effectiveness of each intervention in a high-
risk population. METHODS: The study was performed from the
government payer perspective. Resource utilization was ascer-
tained from published literature and relevant VA databases. Out-
comes data was reviewed and incorporated from published trials
and FDA reviews of teriparatide, alendronate, and risedronate
into an event targeted decision tree model. Pertinent utilization
rates and costs were captured including: emergency services, hos-
pitalization costs associated with fracture, osteoporosis drug
therapy costs, additional medication costs associated with frac-
ture, rehabilitation costs, outpatient visits, and nursing and home
health care costs. Outcome measurements include annualized
cost of treatment per vertebral and non-vertebral fractures over
a 2-year period. The decision tree was built with TreeAge®.
Crystal Ball® 2000 was used to perform the model analysis.
RESULTS: Compared to bisphosphonates, teriparatide demon-
strated fewer osteoporotic fractures and reduced total cost of
treatment. Although the VA medication acquisition cost of teri-
paratide is greater than ten times the cost of bisphosphonates,
this cost is offset by reduction in health care utilization costs.
The primary cost drivers were medications, hospitalizations,
rehabilitation, and nursing home costs. The total cost of treat-
ment for teriparatide was US$1,363,868 versus US$1,776,412
for bisphosphonates, with corresponding fracture rates of 11.35
and 18.19 per 100 patients, respectively. CONCLUSIONS: This
model suggests that teriparatide may be a cost effective therapy
in the treatment of high-risk osteoporosis patients from the per-
spective of the VA. The advantage of teriparatide over bisphos-
phonates may be attributed to the substantial differences in
fracture rates.
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Antiresoprtive therapies are used to prevent further fracture in
men and women with osteoporosis. However, patients with
severe osteoporosis may continue to fracture despite this therapy.
New trials have shown that teriparatide (Forteo) is efﬁcacious in
preventing new vertebral and non-vertebral fractures in patients
who have already experienced a vertebral fracture. OBJEC-
TIVES: This study aimed to assess the cost-effectiveness of teri-
paratide in preventing osteoporotic fractures in this population.
METHODS: A cost-utility model was developed to compare teri-
paratide with no therapy (placebo) in a population of osteo-
porotic patients with prior fracture. This model is a Markov
process estimated using Monte Carlo simulation. Relative efﬁ-
cacy assumptions in the model are based solely on the results of
randomised controlled trials (Neer et al., 2001), while the base-
line probability of fracture is derived from Australian epidemio-
logical data (Sanders et al., 1999). The cost-effectiveness of
teriparatide was assessed in terms of its impact in preventing new
vertebral and non-vertebral fractures in a cohort with at least
one prior radiologically conﬁrmed vertebral fracture and an
average age of 70 years. The model was designed so that the risk
of further vertebral fracture rises with each fracture. The model
ran for a ten-year period. Teriparatide is provided for 18 months,
after which patients have the choice of receiving a bispho-
sphonate or no additional therapy for a further 42 months.
RESULTS: Over the 10-year period, teriparatide is associated
with an increased cost of AUD$7337 ($US5503) and a gain of
0.4168 QALYs per patient compared with no treatment. Hence,
the incremental cost per QALY gained with teriparatide com-
pared with no treatment in this population was AUD$17,603
(US$13,202). Extensive sensitivity analyses indicated these
results were robust. CONCLUSIONS: Teriparatide is a cost-
effective therapy to reduce the risk of future fractures in men and
women with prior osteoporotic vertebral fracture.
